Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Updating Long-Term Outcome of Intermittent Imatinib (INTERIM) Treatment in Elderly Patients with Ph+-CML

Domenico Russo, MD, Giovanni Martinelli, Michele Malagola, Valeria Cancelli, Cristina Skert, MD, Simona Soverini, PhD, Ilaria Iacobucci, PhD, Diamante Turri, Salvatore Mirto, MD, Marco Gobbi, MD, Ivana Pierri, MD, Umberto Vitolo, Patrizia Pregno, MD, Miriam Fogli, Nicoletta Testoni, Antonio De Vivo, Fausto Castagnetti, Enrica Morra, Ester Pungolino, MD, Francesco Di Raimondo, MD, Fabio Stagno, MD PhD, Giuliana Alimena, Massimo Breccia, MD, Francesco Nobile, Bruno Martino, Alessandro Rambaldi, Tamara Intermesoli, MD, Giuseppe Saglio, MD, Giovanna Rege Cambrin, Giuseppe Visani, MD, Giuseppina Nicolini, Paolo de Fabritiis, MD, Elisabetta Abruzzese, MD, Renato Fanin, MD, Mario Tiribelli, MD, Piero Galieni, MD, Catia Bigazzi, Giorgina Specchia, MD, Emanuele Angelucci, Emilio Usala, MD, Caterina Musolino, MD, Sabina Russo, Gianluca Gaidano, MD PhD, Monia Lunghi, MD, Francesco Lauria, MD, Monica Bocchia, MD, Francesco Rodeghiero, Anna D'Emilio, Alberto Bosi, MD, Valeria Santini, Giovanni Quarta, MD, Mariella Girasoli, Giuseppe Fioritoni, MD, Roberto Di Lorenzo, Bruno Mario Cesana, Gianantonio Rosti

Blood (2014) 124 (21): 1794.

https://doi.org/10.1182/blood.V124.21.1794.1794

Published: 2014

Journal Articles

Heterogeneity and Peculiarities Of a Small Series Of Patients Affected By Paroxysmal Nocturnal Hemoglobinuria Treated With Eculizumab

Stefano Pulini, MD, Giuseppina Ricciuti, MD, Simona Sestili, MD, Gaetano La Barba, MD, Antonella Sau, MD, Giuseppe Fioritoni, MD, Paolo Di Bartolomeo, MD

Blood (2013) 122 (21): 4875.

https://doi.org/10.1182/blood.V122.21.4875.4875

Published: 2013

Journal Articles

A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients

Blood (2013) 122 (21): 687.

https://doi.org/10.1182/blood.V122.21.687.687

Published: 2013

Journal Articles

ATRA and Arsenic Trioxide (ATO) Versus ATRA and Idarubicin (AIDA) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia (APL): Results of the Phase III, Prospective, Randomized, Intergroup APL0406 Study by the Italian-German Cooperative Groups Gimema-SAL-AMLSG

Blood (2012) 120 (21): 6.

https://doi.org/10.1182/blood.V120.21.6.6

Published: 2012

Journal Articles

A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM)

Blood (2011) 118 (21): 805.

https://doi.org/10.1182/blood.V118.21.805.805

Published: 2011

Journal Articles

Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year

Domenico Russo, Michele Baccarani, MD, Giovanni Martinelli, MD, Chiara Colombi, Michele Malagola, Cristina Skert, MD, Simona Soverini, Ilaria Iacobucci, PhD, Diamante Turri, MD, Salvatore Mirto, Marco Gobbi, MD, Ivana Pierri, Umberto Vitolo, MD, Patrizia Pregno, MD, Miriam Fogli, Nicoletta Testoni, Antonio De Vivo, Fausto Castagnetti, Enrica Morra, Ester Pungolino, Francesco Di Raimondo, MD, Fabio Stagno, Giuliana Alimena, Massimo Breccia, Francesco Nobile, MD, Bruno Martino, Alessandro Rambaldi, Tamara Intermesoli, Giuseppe Saglio, MD, Giovanna Rege Cambrin, Giuseppe Visani, Giuseppina Nicolini, Paolo de Fabritiis, Elisabetta Abruzzese, Renato Fanin, Mario Tiribelli, Piero Galieni, Catia Bigazzi, Giorgina Specchia, Emanuele Angelucci, Emilio Usala, Caterina Musolino, MD, Sabina Russo, Gianluca Gaidano, Monia Lunghi, M.D., Francesco Lauria, MD, Monica Bocchia, Francesco Rodeghiero, MD, Anna D'Emilio, Alberto Bosi, MD, Valeria Santini, MD, Giovanni Quarta, Mariella Girasoli, Giuseppe Fioritoni, MD, Roberto Di Lorenzo, Bruno Cesana, Gianantonio Rosti, MD

Blood (2011) 118 (21): 1682.

https://doi.org/10.1182/blood.V118.21.1682.1682

Published: 2011

Journal Articles

A Phase II Study of the HDAC Inhibitor Givinostat In Combination with Hydroxyurea In Patients with Polycythemia Vera Resistant to Hydroxyurea Monotherapy

Alessandro Rambaldi, Guido Finazzi, MD, Alessandro M. Vannucchi, MD, Vincenzo Martinelli, MD, Francesco Rodeghiero, MD, Francesco Nobile, MD, Giorgina Specchia, Enrico Maria Pogliani, MD, Odoardo Maria Olimpieri, MD, Giuseppe Fioritoni, MD, Caterina Musolino, MD, Giuseppe Saglio, MD, Piera Sivera, MD, Giovanni Barosi, MD, Silvia Di Tollo, MD, Tiziano Barbui, MD

Blood (2011) 118 (21): 1748.

https://doi.org/10.1182/blood.V118.21.1748.1748

Published: 2011

Journal Articles

Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population

Blood (2011) 118 (17): 4554–4560.

https://doi.org/10.1182/blood-2011-04-347575

Published: 2011

Journal Articles

AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance

Blood (2011) 117 (18): 4716–4725.

https://doi.org/10.1182/blood-2010-08-302950

Published: 2011

Includes: Supplemental data

Journal Articles

Health-Related Quality of Life In Patients with Chronic Myeloid Leukemia Undergoing First Line Treatment with Imatinib for at Least Three Years Compared with the General Population. A Multicenter Study Including 448 Patients

Blood (2010) 116 (21): 2273.

https://doi.org/10.1182/blood.V116.21.2273.2273

Published: 2010

Journal Articles

One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥ 65 years) Ph+ CML Patients – EudraCT Number 2007–005102-42, ClinicalTrials.Gov NCT 00858806.

Domenico Russo, Giovanni Martinelli, Michele Malagola, MD, Chiara Colombi, Giantonio Rosti, Marilina Amabile, Miriam Fogli, Diamante Turri, Salvatore Mirto, Marco Gobbi, Ivana Pierri, Umberto Vitolo, Patrizia Pregno, Enrica Morra, Ester Pungolino, Francesco Di Raimondo, Fabio Stagno, MD, Robin Foà, Giuliana Alimena, Massimo Breccia, Francesco Nobile, Bruno Martino, Alessandro Rambaldi, Tamara Intermesoli, Giuseppe Saglio, Giovanna Rege Cambrin, Giuseppe Visani, Giuseppina Nicolini, Paolo de Fabritiis, Elisabetta Abruzzese, Renato Fanin, Mario Tiribelli, Piero Galieni, Catia Bigazzi, Giorgina Specchia, Vincenzo Liso, MD, Emanuele Angelucci, Emilio Usala, Caterina Musolino, MD, Sabina Russo, Gianluca Gaidano, Monia Lunghi, Francesco Lauria, Monica Bocchia, Francesco Rodeghiero, Anna D'Emilio, Alberto Bosi, Valeria Santini, Giovanni Quarta, Mariella Girasoli, Giuseppe Fioritoni, Roberto Di Lorenzo, Nicoletta Testoni, Antonio De Vivo, Simona Soverini, Ilaria Iacobucci, Michele Baccarani, Michele Baccarani

Blood (2010) 116 (21): 3412.

https://doi.org/10.1182/blood.V116.21.3412.3412

Published: 2010

Journal Articles

GIMEMA-AIEOP AIDA Protocols for the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) In Children: Analysis of 247 Patients Enrolled In Two Sequential Italian Multicenter Trials

Anna Maria Testi, Robin Foa, Gabriella Tomei, Francesco Lo Coco, Andrea Biondi, MD, Andrea Pession, Daniela Diverio, Marco Vignetti, Giuseppe Basso, Franco Locatelli, MD, FRCPath, Carmelo Rizzari, Giuseppe Menna, Maria Luisa Moleti, Nicola Santoro, Giuseppe Fioritoni, Riccardo Masetti, Franco Mandelli

Blood (2010) 116 (21): 871.

https://doi.org/10.1182/blood.V116.21.871.871

Published: 2010

Journal Articles

A Simple Clinical Prognostic Scoring System for Newly Diagnosed Cytogenetically Normal Acute Myeloid Leukemia: a Retrospective Analysis on 530 Patients

Blood (2010) 116 (21): 4848.

https://doi.org/10.1182/blood.V116.21.4848.4848

Published: 2010

Journal Articles

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group

Blood (2010) 116 (17): 3171–3179.

https://doi.org/10.1182/blood-2010-03-276196

Published: 2010

Journal Articles

Long-Term Outcome of 309 Young Patients Affected by Diffuse Large B-Cell Lymphoma (DLBCL) with a Poor-Prognosis at Diagnosis: a Pooled Analysis From Four Consecutive Trials of GIMURELL and Italian Lymphoma Intergroup (IIL).

Blood (2009) 114 (22): 2316.

https://doi.org/10.1182/blood.V114.22.2316.2316

Published: 2009

Journal Articles

Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.

Domenico Russo, Gianantonio Rosti, Giovanni Martinelli, Michele Malagola, Salvatore Mirto, Diamante Turri, Marco Gobbi, Ivana Pierri, Umberto Vitolo, MD, Patrizia Pregno, Francesco Di Raimondo, M.D., Fabio Stagno, Robin Foà, Giuliana Alimena, Massimo Breccia, Francesco Nobile, Bruno Martino, Alessandro Rambaldi, MD, Tamara Intermesoli, Giuseppe Saglio, MD, Giovanna Rege Cambrin, Giuseppe Visani, Giuseppina Nicolini, Paolo de Fabritiis, Elisabetta Abruzzese, Renato Fanin, Mario Tiribelli, Piero Galieni, Catia Bigazzi, Vincenzo Liso, Giorgina Specchia, Emanuele Angelucci, Emilio Usala, Caterina Musolino, Sabina Russo, Gianluca Gaidano, MD, Monia Lunghi, Francesco Lauria, MD, Monica Bocchia, Francesco Rodeghiero, MD, Anna D'Emilio, MD, Giovanni Quarta, Mariella Girasoli, Alberto Bosi, Valeria Santini, Giuseppe Fioritoni, Roberto Di Lorenzo, Chiara Colombi, Miriam Fogli, Marilina Amabile, Nicoletta Testoni, Antonio De Vivo, Michele Baccarani

Blood (2009) 114 (22): 860.

https://doi.org/10.1182/blood.V114.22.860.860

Published: 2009

Journal Articles

Treatment of Adolescents and Young Adults with Acute Lymphoblastic Leukemia (ALL): An Update of the GIMEMA Experience.

Luciana Annino, Marco Vignetti, Francesca Paola Paoloni, Anna Maria Testi, Giovanna Meloni, Giorgina Specchia, Giuseppe Fioritoni, Felicetto Ferrara, Nicola Cantore, Francesco Di Raimondo, Francesco Fabbiano, Andrea Camera, MD, Enrica Morra, MD, Pietro Leoni, Paola Fazi, Robert Foa, Franco Mandelli, Sergio Amadori, M.D.

Blood (2009) 114 (22): 3097.

https://doi.org/10.1182/blood.V114.22.3097.3097

Published: 2009

Journal Articles

Extramedullary Relapses After Stem Cell Transplantation in Multiple Myeloma.

Stefano Pulini, MD, Annalisa Natale, MD, Anna Maria Morelli, MD, Antonio Spadano, MD, Daniela Carlino, MD, Francesca Fioritoni, MD, Patrizia Marani Toro, MD, Paolo Di Bartolomeo, MD, Giuseppe Fioritoni, MD

Blood (2009) 114 (22): 4959.

https://doi.org/10.1182/blood.V114.22.4959.4959

Published: 2009

Journal Articles

Efficacy and Safety of a First-Line Combined Therapeutic Approach for Young CLL Patients Stratified According to the Biological Prognostic Features: First Analysis of the GIMEMA Multicenter LLC0405 Study

Blood (2008) 112 (11): 3167.

https://doi.org/10.1182/blood.V112.11.3167.3167

Published: 2008

NARROW

Updating Long-Term Outcome of Intermittent Imatinib (INTERIM) Treatment in Elderly Patients with Ph+-CML

Heterogeneity and Peculiarities Of a Small Series Of Patients Affected By Paroxysmal Nocturnal Hemoglobinuria Treated With Eculizumab

A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients

ATRA and Arsenic Trioxide (ATO) Versus ATRA and Idarubicin (AIDA) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia (APL): Results of the Phase III, Prospective, Randomized, Intergroup APL0406 Study by the Italian-German Cooperative Groups Gimema-SAL-AMLSG

A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM)

Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year

A Phase II Study of the HDAC Inhibitor Givinostat In Combination with Hydroxyurea In Patients with Polycythemia Vera Resistant to Hydroxyurea Monotherapy

Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population

AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance

Health-Related Quality of Life In Patients with Chronic Myeloid Leukemia Undergoing First Line Treatment with Imatinib for at Least Three Years Compared with the General Population. A Multicenter Study Including 448 Patients

One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥ 65 years) Ph+ CML Patients – EudraCT Number 2007–005102-42, ClinicalTrials.Gov NCT 00858806.

GIMEMA-AIEOP AIDA Protocols for the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) In Children: Analysis of 247 Patients Enrolled In Two Sequential Italian Multicenter Trials

A Simple Clinical Prognostic Scoring System for Newly Diagnosed Cytogenetically Normal Acute Myeloid Leukemia: a Retrospective Analysis on 530 Patients

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group

Long-Term Outcome of 309 Young Patients Affected by Diffuse Large B-Cell Lymphoma (DLBCL) with a Poor-Prognosis at Diagnosis: a Pooled Analysis From Four Consecutive Trials of GIMURELL and Italian Lymphoma Intergroup (IIL).

Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.

Treatment of Adolescents and Young Adults with Acute Lymphoblastic Leukemia (ALL): An Update of the GIMEMA Experience.

Extramedullary Relapses After Stem Cell Transplantation in Multiple Myeloma.

Bortezomib as Front-Line Therapy in Primary Plasma Cell Leukemia

Efficacy and Safety of a First-Line Combined Therapeutic Approach for Young CLL Patients Stratified According to the Biological Prognostic Features: First Analysis of the GIMEMA Multicenter LLC0405 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only